Company intelligence / Profile preview

Xitra Therapeutics

Toronto, Ontario, Canada

Ownership: Private
Development stage: Other

Overview

Xitra Therapeutics is a preclinical-stage biotechnology company focused on developing first-in-class therapeutics for hard-to-treat cancers. The company's primary focus is on inhibiting the MYC oncogene, a central driver in many cancers that has historically been considered undruggable. Utilizing a proprietary delivery platform, Xitra aims to deliver peptide-based inhibitors directly into the cell nucleus to disrupt oncogenic signaling. The company was spun out of the Ontario Institute for Cancer Research (OICR) and University Health Network (UHN) and is supported by FACIT.

Therapeutic areas: Oncology
Modalities: Peptides
Industry: Biotech

Drug pipeline

1 asset

XITRA

Preclinical

Partnerships

Ontario Institute for Cancer ResearchUniversity Health Network

Beyond the preview

Go deeper on Xitra Therapeutics.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Xitra Therapeutics.

Explore the full profile